232 related articles for article (PubMed ID: 30425121)
1. Apocrine lesions of the breast: part 2 of a two-part review. Invasive apocrine carcinoma, the molecular apocrine signature and utility of immunohistochemistry in the diagnosis of apocrine lesions of the breast.
D'Arcy C; Quinn CM
J Clin Pathol; 2019 Jan; 72(1):7-11. PubMed ID: 30425121
[TBL] [Abstract][Full Text] [Related]
2. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
3. An Update on the Molecular and Clinical Characteristics of Apocrine Carcinoma of the Breast.
Vranic S; Gatalica Z
Clin Breast Cancer; 2022 Jun; 22(4):e576-e585. PubMed ID: 35027319
[TBL] [Abstract][Full Text] [Related]
4. Apocrine lesions of the breast: part 1 of a two-part review: benign, atypical and in situ apocrine proliferations of the breast.
D'Arcy C; Quinn C
J Clin Pathol; 2019 Jan; 72(1):1-6. PubMed ID: 30409840
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ.
Gatalica Z
Pathol Res Pract; 1997; 193(11-12):753-8. PubMed ID: 9521507
[TBL] [Abstract][Full Text] [Related]
6. Expression of androgen receptors and inhibin/activin alpha and betaA subunits in breast apocrine lesions.
Shim HS; Jung WH; Kim H; Park K; Cho NH
APMIS; 2006 May; 114(5):352-8. PubMed ID: 16725011
[TBL] [Abstract][Full Text] [Related]
7. Bilateral apocrine carcinoma of the breast. Molecular and immunocytochemical evidence for two independent primary tumours.
Schmitt FC; Soares R; Seruca R
Virchows Arch; 1998 Dec; 433(6):505-9. PubMed ID: 9870682
[TBL] [Abstract][Full Text] [Related]
8. Apocrine lesions of the breast.
Quinn CM; D'Arcy C; Wells C
Virchows Arch; 2022 Jan; 480(1):177-189. PubMed ID: 34537861
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical and molecular profiling of histologically defined apocrine carcinomas of the breast.
Vranic S; Marchiò C; Castellano I; Botta C; Scalzo MS; Bender RP; Payan-Gomez C; di Cantogno LV; Gugliotta P; Tondat F; di Celle PF; Mariani S; Gatalica Z; Sapino A
Hum Pathol; 2015 Sep; 46(9):1350-9. PubMed ID: 26208846
[TBL] [Abstract][Full Text] [Related]
10. Pure Apocrine Carcinomas Represent a Clinicopathologically Distinct Androgen Receptor-Positive Subset of Triple-Negative Breast Cancers.
Mills AM; E Gottlieb C; M Wendroth S; M Brenin C; Atkins KA
Am J Surg Pathol; 2016 Aug; 40(8):1109-16. PubMed ID: 27259012
[TBL] [Abstract][Full Text] [Related]
11. Apocrine carcinoma of the breast: A brief update on the molecular features and targetable biomarkers.
Vranic S; Feldman R; Gatalica Z
Bosn J Basic Med Sci; 2017 Feb; 17(1):9-11. PubMed ID: 28027454
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of androgen receptor and forkhead-box A1 protein in apocrine breast carcinoma.
Sasahara M; Matsui A; Ichimura Y; Hirakata Y; Murata Y; Marui E
Anticancer Res; 2014 Mar; 34(3):1261-7. PubMed ID: 24596370
[TBL] [Abstract][Full Text] [Related]
13. Apocrine carcinoma of the breast: a comprehensive review.
Vranic S; Schmitt F; Sapino A; Costa JL; Reddy S; Castro M; Gatalica Z
Histol Histopathol; 2013 Nov; 28(11):1393-409. PubMed ID: 23771415
[TBL] [Abstract][Full Text] [Related]
14. AMACR Expression is a Potential Diagnostic Marker in Apocrine Lesions of Breast, and is Associated with High Histologic Grade and Lymph Node Metastases in Some Invasive Apocrine Breast Cancers.
Lerner G; Tang H; Singh K; Golestani R; St Claire S; Humphrey PA; Lannin D; Janostiak R; Harigopal M
Clin Breast Cancer; 2023 Feb; 23(2):199-210. PubMed ID: 36577560
[TBL] [Abstract][Full Text] [Related]
15. Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast.
Honma N; Takubo K; Akiyama F; Sawabe M; Arai T; Younes M; Kasumi F; Sakamoto G
Histopathology; 2005 Aug; 47(2):195-201. PubMed ID: 16045781
[TBL] [Abstract][Full Text] [Related]
16. Molecular characterization of apocrine carcinoma of the breast: validation of an apocrine protein signature in a well-defined cohort.
Celis JE; Cabezón T; Moreira JM; Gromov P; Gromova I; Timmermans-Wielenga V; Iwase T; Akiyama F; Honma N; Rank F
Mol Oncol; 2009 Jun; 3(3):220-37. PubMed ID: 19393583
[TBL] [Abstract][Full Text] [Related]
17. Androgen and estrogen receptor mRNA status in apocrine carcinomas.
Bratthauer GL; Lininger RA; Man YG; Tavassoli FA
Diagn Mol Pathol; 2002 Jun; 11(2):113-8. PubMed ID: 12045715
[TBL] [Abstract][Full Text] [Related]
18. Loss of periostin/OSF-2 in ErbB2/Neu-driven tumors results in androgen receptor-positive molecular apocrine-like tumors with reduced Notch1 activity.
Sriram R; Lo V; Pryce B; Antonova L; Mears AJ; Daneshmand M; McKay B; Conway SJ; Muller WJ; Sabourin LA
Breast Cancer Res; 2015 Jan; 17(1):7. PubMed ID: 25592291
[TBL] [Abstract][Full Text] [Related]
19. The role of histopathologic testing on apocrine carcinoma of the breast.
Ilhan B; Emiroğlu S; Türkay R; Ilhan R
Curr Probl Cancer; 2020 Apr; 44(2):100501. PubMed ID: 31521370
[TBL] [Abstract][Full Text] [Related]
20. Molecular pathology of breast apocrine carcinomas: a protein expression signature specific for benign apocrine metaplasia.
Celis JE; Gromova I; Gromov P; Moreira JM; Cabezón T; Friis E; Rank F
FEBS Lett; 2006 May; 580(12):2935-44. PubMed ID: 16631754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]